Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biologics in severe asthma: the role of real-world evidence from registries
Giovanni Paoletti, J. Pepys, Marta Casini, et al.
European Respiratory Review (2022) Vol. 31, Iss. 164, pp. 210278-210278
Open Access | Times Cited: 21

Showing 21 citing articles:

Severe asthma care trajectories: the French RAMSES cohort
Jeanne‐Marie Perotin, Lisa Gauquelin, N. Just, et al.
ERJ Open Research (2024) Vol. 10, Iss. 2, pp. 00837-2023
Open Access | Times Cited: 4
Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR
So‐Young Park, Sun-Kyung Lee, Woo‐Jung Song, et al.
Allergy Asthma and Immunology Research (2024) Vol. 16, Iss. 3, pp. 253-253
Open Access | Times Cited: 4
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
Johannes A. Kroes, Rafael Alfonso‐Cristancho, Aruna T. Bansal, et al.
ERJ Open Research (2023) Vol. 9, Iss. 2, pp. 00745-2022
Open Access | Times Cited: 8
Adult Severe Asthma Registries: A Global and Growing Inventory
Breda Cushen, Mariko Siyue Koh, Trung N. Tran, et al.
Pragmatic and Observational Research (2023) Vol. Volume 14, pp. 127-147
Open Access | Times Cited: 8
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
Eve Denton, Mark Hew, Matthew Peters, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2700-2716
Open Access | Times Cited: 2
Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease—A Systematic Review
Ophir Freund, Ori Wand, Sara Kutzkel, et al.
Diagnostics (2024) Vol. 14, Iss. 21, pp. 2390-2390
Open Access | Times Cited: 2
Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study
Philippine Lifar, François Montastruc, Laurent L. Reber, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 207, Iss. 9, pp. 1253-1255
Open Access | Times Cited: 5
Roles of real-world evidence in severe asthma treatment: challenges and opportunities
Young‐Soo Lee, Ji‐Hyang Lee, So Young Park, et al.
ERJ Open Research (2022) Vol. 9, Iss. 2, pp. 00248-2022
Open Access | Times Cited: 9
Management of Chronic Asthma in Adults
Huong Q. Nguyen, Munima Nasir
Medical Clinics of North America (2024) Vol. 108, Iss. 4, pp. 629-640
Closed Access | Times Cited: 1
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists
Giovanni Costanzo, Cristiano Caruso, Giovanni Paoletti, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 8, pp. 854-854
Open Access | Times Cited: 1
Next generation health guidelines: The role of real‐life data in evidence‐based medicine
Giorgio Walter Canonica, Ioana Agache, Holger J. Schünemann, et al.
Allergy (2023) Vol. 79, Iss. 1, pp. 12-14
Open Access | Times Cited: 4
Montelukast as a potential treatment for COVID-19
Matthew W. McCarthy
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 5, pp. 551-555
Closed Access | Times Cited: 3
Management of Chronic Asthma in Adults
Huong Q. Nguyen, Munima Nasir
Primary Care Clinics in Office Practice (2023) Vol. 50, Iss. 2, pp. 179-190
Closed Access | Times Cited: 2
Real-world data: A relevant component in the framework of scientific evidence
Giorgio Walter Canonica, Lorenzo Del Moro, Giovanni Costanzo, et al.
Asia Pacific Allergy (2023) Vol. 13, Iss. 1, pp. 40-43
Open Access | Times Cited: 2
Real-life studies and registries of severe asthma: The advent of digital technology
Veronika Urdova, Linda Rogers, Miloš Jeseňák, et al.
Respiratory Medicine (2023) Vol. 220, pp. 107429-107429
Open Access | Times Cited: 2
Immunobiological therapy in the treatment of severe asthma
David Evangelista Barros de Oliveira, Carlos Gustavo Alves Leitão, F Falcão, et al.
Research Society and Development (2024) Vol. 13, Iss. 5, pp. e14513545933-e14513545933
Open Access
Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, et al.
World Allergy Organization Journal (2024) Vol. 18, Iss. 1, pp. 101016-101016
Open Access
A case of biologic use in acute asthma exacerbation refractory to conventional management
Bo‐Guen Kim, Dong Won Park, Tai Sun Park, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2922-2925
Closed Access
Editorial: pharmacotherapy and evidence-based medicine section
Giovanni Paoletti, Giovanni Costanzo, Lorenzo Del Moro, et al.
Current Opinion in Allergy and Clinical Immunology (2023) Vol. 23, Iss. 4, pp. 307-308
Closed Access
Preventive effects of probiotics on asthmatic lung inflammation in an ovalbumin-induced murine model
Tae Il Park, Jin Yong Song, Yubin Lee, et al.
Research Square (Research Square) (2023)
Open Access
What have we learnt from real‐life research in asthma and COPD? Standards and novel designs for the future
David Price, Thendral Uthaman
Respirology (2022) Vol. 27, Iss. 12, pp. 1018-1021
Open Access
Page 1

Scroll to top